NRX Pharmaceuticals (NRXP) Income from Continuing Operations (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Income from Continuing Operations of 4970000.0 for Q1 2026, down 29.33% year-over-year from 7032293.81 in Q1 2025, and down 1.08% quarter-over-quarter from 4917000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Income from Continuing Operations (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Income from Continuing Operations for 10 consecutive years, with 4970000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 29.33% year-over-year to 4970000.0; the TTM figure through Mar 2026 stood at 17826000.0 (down 10.11% YoY), while the FY2025 annual figure was 67412000.0, up 1.04% from the prior year.
- Income from Continuing Operations fell to 4970000.0 in Q1 2026 per NRXP's latest filing, from 4917000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2284000.0 in Q4 2024 and bottomed at 16711000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 6542058.82 across 5 years, with a median of 4970000.0 in 2026.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 8190.75% — and 2023, when it surged 76.26%.
- NRX Pharmaceuticals' Income from Continuing Operations stood at 12307000.0 in 2022, then soared by 63.3% to 4517000.0 in 2023, then soared by 49.44% to 2284000.0 in 2024, then tumbled by 115.28% to 4917000.0 in 2025, then decreased by 1.08% to 4970000.0 in 2026.
- Business Quant data shows NRXP's Income from Continuing Operations at 4970000.0 in Q1 2026, 4917000.0 in Q4 2025, and 4211000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | -6.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.97 Mn |
| Dec 31, 2025 | -4.92 Mn |
| Sep 30, 2025 | -4.21 Mn |
| Jun 30, 2025 | -3.73 Mn |
| Mar 31, 2025 | -3.84 Mn |
| Dec 31, 2024 | -2.28 Mn |
| Sep 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -7.04 Mn |
| Mar 31, 2024 | -6.35 Mn |
| Dec 31, 2023 | -4.52 Mn |
| Sep 30, 2023 | -6.19 Mn |
| Jun 30, 2023 | -8.09 Mn |
| Mar 31, 2023 | -3.97 Mn |
| Dec 31, 2022 | -12.31 Mn |
| Sep 30, 2022 | -9.32 Mn |
| Jun 30, 2022 | -9.75 Mn |
| Mar 31, 2022 | -16.71 Mn |
| Dec 31, 2021 | -30.41 Mn |
| Sep 30, 2021 | -37.05 Mn |
| Jun 30, 2021 | -117,613.00 |